Description
Xarelto (Rivaroxaban) Coated Tablets 10 mg. №10
Ingredients:
Each coated tablet contains 10 mg of rivaroxaban.
Mechanism of Action:
Rivaroxaban, the active ingredient in Xarelto, is a direct Factor Xa inhibitor. It selectively blocks the active site of Factor Xa, an essential enzyme in the coagulation cascade. By inhibiting Factor Xa, rivaroxaban prevents the formation of thrombin and subsequent blood clot formation.
Pharmacological Properties:
Xarelto exhibits anticoagulant properties by specifically targeting Factor Xa and interfering with the coagulation process, thereby reducing the risk of thrombotic events.
Indications for Use:
Xarelto is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
Contraindications:
Do not administer Xarelto to patients with active pathological bleeding or those with a history of hypersensitivity reactions to rivaroxaban.
Side Effects:
Common side effects of Xarelto may include bleeding, bruising, and gastrointestinal discomfort. Patients should seek medical attention if they experience severe or persistent bleeding.
Usage Instructions:
The recommended dosage of Xarelto is one 10 mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed, chewed, or broken before ingestion.
Benefits Compared to Analogues:
Xarelto offers the advantage of rapid onset of action and does not necessitate regular monitoring of coagulation levels, providing a convenient option for patients requiring anticoagulation therapy.
Suitable Patient Groups:
Xarelto can be used in various patient populations, including adults, but specific dosing adjustments may be necessary for elderly individuals or those with renal impairment. It is not recommended for use in children.
Storage and Shelf Life:
Xarelto should be stored at room temperature away from moisture and heat. The shelf life of the product is as indicated on the packaging.
Packaging Description:
Xarelto is available in blister packs containing 10 coated tablets of 10 mg strength each. The packaging should be kept intact until the tablets are ready to be taken.
Clinical Evidence and Effectiveness:
Clinical studies, such as the ROCKET AF study, have demonstrated the efficacy of Xarelto in reducing the risk of stroke and systemic embolism in patients with atrial fibrillation when compared to traditional anticoagulants like warfarin. Moreover, Xarelto has shown a similar safety profile to existing treatments.
